GLP-1 side effects by dose step: nausea, constipation, when to stop

The starting step, semaglutide 0.25 mg, tirzepatide 2.5 mg or retatrutide 1 to 2 mg, is a tolerance dose. The compound pages describe the first four weeks as mild appetite reduction, early fullness after small meals, some nausea and little weight change for semaglutide, with tirzepatide producing a more noticeable appetite drop even at 2.5 mg. Burping and reflux appear as the stomach empties more slowly, and some people feel tired because they are eating less.

Most of this is mild and improves within the four weeks. The point of the step is to let the gut adapt before the dose that actually suppresses appetite arrives. People who skip it, which happens on the grey market because no starter pen is dispensed, report the nausea the step was designed to prevent. The semaglutide and tirzepatide dosage charts lay out the schedules.

Each increase restarts the clock. The compound pages for both approved drugs describe the same shape: a flare of nausea, burping, reflux and either constipation or diarrhea for a week or two after each step as blood levels climb toward the new steady state, then a settling. With half-lives of 5 to 7 days, the new level is reached at about three weeks, which is why a step that still feels bad at week four is a reason to hold rather than climb.

Nausea is the headline but constipation is the one that persists. Slowed gastric emptying and reduced food volume together mean less bulk moving through, and constipation tends to appear in the middle steps and stay unless managed. Diarrhea is more often an early and transient effect. Reflux and burping are worst after larger meals and in the evening, which is one reason people inject at night so the first day of peak effect lands during sleep.

Higher steps carry the same effects more often and more intensely. In the trials, discontinuation for adverse events rose with dose. The semaglutide compound page says escalating too fast is the number one mistake; the tirzepatide page says to stay another month at a step that causes persistent nausea. Retatrutide's early weeks are described as rougher than semaglutide, with the glucagon component adding to the GI load.

On January 29, 2026 the UK MHRA issued a drug safety alert about acute pancreatitis as an infrequent but potentially fatal side effect of GLP-1 receptor agonists. The alert reinforced what the product labels already carry: pancreatitis is rare, it has been reported with every drug in the class, and it is serious enough that the symptoms need to be recognized early. The alert asked clinicians to counsel patients on the signs and to stop the drug if pancreatitis is suspected.

The sign is severe, persistent abdominal pain, often in the upper abdomen and often radiating to the back, with or without vomiting. It is not the ordinary nausea and fullness of titration, which come and go with meals and improve over days. Pancreatitis pain does not improve and usually gets worse. The compound pages for semaglutide, tirzepatide and retatrutide all list it as the first stop signal.

The alert applies to the class, which includes compounded and grey-market product and, by pharmacology, retatrutide and cagrilintide even though neither has a label. Anyone with a history of pancreatitis is in a higher-risk group on every label. Are peptides safe covers the general safety picture, and the peptide side effects article covers the non-GLP-1 compounds.

Gallstones and gallbladder inflammation are more common with rapid weight loss of any kind, and GLP-1 drugs produce rapid weight loss. The labels for semaglutide and tirzepatide both list gallbladder disease, and the trials recorded more cholelithiasis and cholecystitis on drug than on placebo. The mechanism is partly the rate of loss itself, which changes bile composition, and partly slowed gallbladder emptying.

The signs are pain under the right ribs, especially after fatty meals, fever, yellowing of the skin or eyes, or pale stools. The compound pages list these as stop signals. Unlike titration nausea, gallbladder pain is localized and often comes in waves. Slower weight loss, which usually means holding a lower dose step longer, is the one modifiable factor; the compound pages frame gallstones alongside hair shedding and lean mass loss as rate-of-loss effects.

All GLP-1 drugs raise resting heart rate by a small amount, typically a few beats per minute. Retatrutide raises it more. The compound page reports a rise of several beats per minute in the early months that drifts back toward baseline over time, and attributes it to the glucagon component. The brief summary of the 2026 phase 3 topline is that heart rate remains the extra safety signal versus tirzepatide.

Practically, that means two things. Stimulants compound it: the compound page flags caffeine, pre-workouts and decongestants as things that stack with the effect, and suggests easing off intense training right after a dose step. And there is a stop threshold: the compound page lists a resting heart rate that stays more than about 20 beats above baseline, or palpitations, as a reason to stop. People with arrhythmias or uncontrolled blood pressure are flagged for caution.

Whether the rise matters over years is unknown, because retatrutide has no cardiovascular outcomes trial. The retatrutide phase 3 results article covers what is and is not known, and retatrutide vs tirzepatide compares the two.

Hair shedding a few months into rapid weight loss is listed on both the semaglutide and tirzepatide compound pages. It is telogen effluvium, the same diffuse shedding that follows surgery, illness or a crash diet, triggered by the energy deficit rather than the molecule. It typically starts two to four months into fast loss, lasts a few months and regrows once weight stabilizes. Faster loss means more shedding.

Lean mass loss sits in the same category. Reviews estimate 30 to 40 percent of weight lost on GLP-1 drugs is fat-free mass, and the counters with evidence are resistance training and protein. Muscle loss on GLP-1 drugs covers it in full. Fatigue and reduced exercise tolerance in the early weeks of each step are also mostly a food intake effect and ease as intake stabilizes.

The most consistent report, and the one the compound pages make, is slower titration. Holding each step for 8 weeks instead of 4, or dropping back a step after a bad increase, costs time and nothing else. Both labels increase only as tolerated, so a slow climb is within them. Starting at the tolerance dose rather than skipping it is the same principle applied to week one.

Smaller meals eaten slowly, stopping at the first sign of fullness, and avoiding large fatty meals in the evening address the reflux and nausea that come from a stomach that empties slowly. Many people inject in the evening so the roughest hours of a new step land during sleep. For constipation, fluid, fibre and movement are the usual first steps, and the compound pages note that the drug reduces food volume enough that bulk has to be deliberate. Alcohol makes nausea, reflux and dehydration worse and the semaglutide page flags that tolerance for it drops.

Titration nausea is unpleasant and expected. The following are not, and the compound pages list each as a stop signal: severe or persistent abdominal pain, especially radiating to the back (possible pancreatitis); pain under the right ribs with fever, yellowing or pale stools (possible gallbladder disease); vomiting or diarrhea severe enough to cause dehydration or dizziness on standing, or vomiting that prevents keeping fluids down for more than a day; a lump in the neck, hoarseness or trouble swallowing (the thyroid warning); and, for retatrutide, a resting heart rate that stays well above baseline or palpitations.

Add vision changes in anyone with diabetes, signs of low blood sugar in anyone combining a GLP-1 drug with insulin or a sulfonylurea, and skin sensations that spread or worsen rather than fade on retatrutide. People using compounded or grey-market product have the same red flags with less supervision, which is the argument the buying guide makes for involving a clinician even when the vial did not come from one. Slowed gastric emptying also matters before any anesthesia, and the labels say to tell the anesthesiologist.